Celltrion Inc
068270
Company Profile
Business description
Celltrion Inc is a Korea-based company principally engaged in the research, development, and manufacture of therapeutic proteins. The company mainly manufactures biosimilar products, which are used to treat breast cancer, rheumatoid arthritis disease, Crohn's disease, Hodgkin's lymphoma, colorectal cancer, rheumatoid arthritis, respiratory syncytial virus, colon cancer, and others.
Contact
13-6 SongDo-Dong
Yeonsu-gu
Incheon City406-840
KORT: +82 32855000
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
2,572
Stocks News & Analysis
stocks
Going into earnings, is Nvidia stock a buy, a sell, or fairly valued?
Watching the data centre business and the debate around it, here’s what we think of Nvidia stock.
stocks
2 undervalued ASX shares report
These two ASX shares are trading at a discount to our fair value.
stocks
Turmoil at WiseTech
Board members step down over differences on the role of former CEO Richard White.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,498.00 | 62.10 | -0.73% |
| CAC 40 | 8,096.93 | 5.94 | 0.07% |
| DAX 40 | 22,461.40 | 35.47 | 0.16% |
| Dow JONES (US) | 43,461.21 | 33.19 | 0.08% |
| FTSE 100 | 8,698.13 | 39.15 | 0.45% |
| HKSE | 23,034.02 | 307.59 | -1.32% |
| NASDAQ | 19,286.93 | 237.08 | -1.21% |
| Nikkei 225 | 38,237.79 | 539.15 | -1.39% |
| NZX 50 Index | 12,307.27 | 224.45 | -1.79% |
| S&P 500 | 5,983.25 | 29.88 | -0.50% |
| S&P/ASX 200 | 8,251.90 | 56.30 | -0.68% |
| SSE Composite Index | 3,346.04 | 26.99 | -0.80% |